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at www.jvascsurg.org.DISCUSSIONDr Julie Ann Freischlag (Baltimore, Md). As you probably
are aware, we presented some results from UCLA about 13 years
ago that actually at that time showed that there was adequate fund-
ing for the grafts at that time even though they did contribute to
that high cost. And one of my greatest worries has been is when is
the day going to be that we cannot afford to do this? I guess that
day is today! Internationally, in many countries only those who can
afford to individually pay for high priced technology receive it.
My question to you is about the Veterans Affairs (VA). As you
know, we published the cost of the endovascular graft in the VA
setting and actually came out with the statement in our paper
that it actually was not more costly because the way accounting
is done in the VA system. All costs are spread like butter. So that
in the OVER trial, the endovascular grafts were not more expen-
sive than the open graft in that cost setting.
Do you think perhaps as we go ahead with health care reform
this could be the way costs of hospitalization are distributedd
spread across all patientsdlike butter?
Dr Stone. I think that is an interesting question. It is often
difﬁcult to extrapolate practice patterns in the VA system to the
university system. Clearly, at Dartmouth, where the whole
accountable care organization, ACO model, is being championed,
much scrutiny is being placed on individual procedure ﬁnances.
Certainly, the idea of cost sharing is an interesting one.
Currently at our institution we are even looking at care
delivery in a more granular fashion, a patient-focused economic
analysis, or PFEA. Therefore, even in a less magniﬁed view, if lesser
cost procedures were able to counteract some of the cost impact of
EVAR, I suspect from our hospital administration’s standpoint, an
unsustainable procedure-associated margin for EVAR is likely not
going to be a good practice pattern for long-term care.
Dr Freischlag. I think in the VA they did not ask anybody,
they just did it.
Dr W. Charles Sternbergh (New Orleans, La). I enjoyed
your paper very much and it is like kind of déjà vu all over again.
At the Society for Vascular Surgery meeting in 1999, I presented
data very similar to this. It was 3 months before the ﬁrst commer-
cial devices became available in the United States. And much to
everybody’s shock and surprise, we found the same thing. There
were higher costs for endovascular AAA repair, with the endograft
cost about 50% of the total hospital cost. I naively opined then that
surely these prices would come down as more competitors came
into the market; but endografts have gone from $8500 to
$9000 then, to about $15,000 to $18,000 now. So that has really
not happened.
I very much agree with your assessment that we in vascular
surgery must take a leadership role in raising awareness of these
hospital costs for endovascular aneurysm repair. Most vascular
specialists are unaware of these cost issues.
I have one question for you. Why did you exclude all of your
patients that were coded into DRG 237? Those are patients that, as
you suggested, have higher costs, but they also have higher
reimbursement.
Dr Stone. We chose to exclude those patients, with major
complications, billed using DRG 237, because we thought they
represented a different subset of EVAR treated patients. The
cost proﬁle and DRG remuneration, as you point out, is different.
We thought that our ﬁrst foray into this analysis would be to
look at the most simple EVARs, if you will, the so-calledapple-on-a-stick EVAR cases where other cost driving factors,
such as length of stay would not necessarily confound our analysis.
Moreover, when we looked at our DRG 237 billed volume,
we had roughly 12 patients over the study interval in that group
and, thus, chose to exclude them.
Since you made the point of graft prices and the lack of change
over time, I would add that we were somewhat surprised by these
ﬁndings. Moreover, in our own practice, we historically have not
factored device cost in case planning paradigms.
I would argue one potential reason why we have not seen
device cost reduction, across the country, is the obfuscation of
pricing by a myriad of reasons. As an example for instance, the
price we get at Dartmouth may not be the same price that you
are paying for the identical graft at your institution, which is alto-
gether different from the price that we pay for a different manufac-
turer and so forth. I think that this inherent lack of transparency
has led to this sustained practice pattern.
Dr Frank Sharp (Brick, NJ). You have partially answered my
question with your previous comments. Are you aware of any data
outside of the United States in terms of a similar analysis for the
cost for the devices? I think as vascular surgeons we need to
have these companies compete a little bit, and if these devices
are provided outside the United States for substantially less cost,
we should be aware of that.
Dr Stone. I agree completely. Yesterday I received the Wylie
Traveling Fellowship Award and that is exactly what our applica-
tion is about. We plan to examine this issue in Europe and look
at the cost of devices in different capitated systems for comparison.
But you are potentially correct that a lack of transparency in the
health care economics of our country may go a long way in subsi-
dizing expensive devices in other parts of the world.
Dr Krish Soundararajan (Wilmington, Del). This is a very
timely paper. I think it is naive for vascular surgeons to consider
treatment and therapies without understanding the cost factor.
However, I had a couple of concerns. I hope there is no Chief
Financial Ofﬁcer or Chief Executive Ofﬁcer in the audience here. I
would be concerned how they may hear your conclusion and be
adversely inﬂuenced on their support to develop programs that
embrace advanced technology.
I would like to suggest the way to look at this would be not to
include cost of endograft alone but to see how the hospital makes
revenue from the secondary aspects of an endograft. The patients
go through many computed tomography scans and utilize so many
other services and those could certainly very well make revenue for
the hospitals.
My ﬁrst question would be: When you analyzed the data, did
you include the modiﬁers for comorbidities? If you use the modi-
ﬁer in ICD coding, as per my understanding, the DRG payments
are likely to be better.
And the second question: If you think the cost of this is solely
driven by endograft, would it be fair to say there is very little we
can do as physicians?
Dr Stone. To your point about other aspects of EVAR that
generate revenue for health systems (ie, the CAT scans and so
forth), I think all politics is local. Where we practice medicine,
a so-called model of destination care exists. Speciﬁcally, many of
the EVARs that we perform are on patients who are seen and
imaged at smaller surrounding hospitals. And likewise those
follow-up computed tomography scans are often not performed
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do not derive any of the additional associated revenue you are
alluding to. I think this is a trend that may be pervasive for other
tertiary care referral centers around the country.
We did look at all of our EVARs. I do not think I could give
you an exact number of the number of our cases in our study
cohort who had modiﬁers attached to the DRG payment.
As to what we, physicians can do to address costs, I think that
is the big question. I think there are potentially many things we can
do at a microlevel, in our own respective environments. For
instance, if you look at our total EVAR practice, we estimate
that we can treat roughly 40% of our EVARs using any commer-
cially available device interchangeably with no impact to our
patients. Clearly, there is a cost implication of doing that and so
we can impact practice in that capacity. Ultimately, we need to
create an environment of cost transparency. If someone goes to
buy a car, one knows what the “Kelley Blue Book value” of that
car is when you are negotiating a price with your dealer. Thus
far, that does not exist in our profession. From a hospital and
surgeon standpoint, there is not a good reason why we cannot ulti-
mately try to impact that.
Dr Pathanjali Sharma (Reading, Pa). Is your data granular
enough to ﬁgure out what is the cost of the ancillary products
that we use during endografting, such as balloons, catheters,
sheaths, contralateral access, and extensions? Because that will
substantially add to the cost as I understand it.
Dr Stone. You raise a good point. We did look at that. And
again, that is part of the reason why we tried to start with
a more simple case complexity patient cohort, where a lot of
adjunctive supplies and so forth might confound cost analyses.
When examined, different catheters, closure devices for percuta-
neous access, wires and so forth, even when considered in aggre-
gate had a much smaller impact compared with the various stent
graft implantables.
Dr Michael Conte (San Francisco, Calif). David, I think your
paper is really important, particularly given that it is more than
a decade since Dr Sternbergh’s paper essentially showed similar
things. And today, although the technology for EVAR has pla-
teaued, we have not seen the reductions in costs or price that
would normally be associated with the market evolution of a tech-
nology in that way.
I can assure you we have the same issue at our institution.
And I just want to point out that you are looking at direct costs,but you did not even account for indirect costs such as keeping
the lights on and the mortars and bricks for the institution. For
every dollar in direct patient care costs at my hospital, it takes
60 cents to take out the garbage, keep the lights on, maintain
the physical plant, etc. And so, when they look at proﬁtability
and add the additional indirect costs, it looks even worse for an
EVAR case.
So I guess the point here is, is it not feasible that the vendor
costs for these devices could come down by 20% or 25% in the
environment where we now have ﬁve or six choices between
endografts for AAA, which would really make the procedures
almost revenue neutral?
My other question is: Did you look at patient factors such as
anatomy, age, or other comorbidities that could affect either the
revenue (ie, coding) or the cost side?
Dr Stone. To address the second point in your question ﬁrst,
we tried to anatomically derive a subset of patients, in whom we
thought anatomy was consistent, which we felt would impact
requisite devices and thus case-associated costs. We did not adjust
for age. There may be some small disparities within that group in
terms of comorbidity proﬁle which we did not account for. But
from a cost and anatomy standpoint, we thought this study group
would be anatomically more homogeneous.
To your point about being more revenue neutral, I would
agree, but add that our operating margins did include allocated
costs and, thus, some institutional overhead costs. I would agree,
however, that it is not unfeasible to aim for a 20% cost reduction
to make this a more revenue neutral procedure.
I know our orthopedic colleagues have been successful in
negotiating substantial reductions in price for their devices,
moving to fewer vendors for joint replacement. Obviously, for
reasons that are not equivalent, we are not willing to, at this point,
go to an exclusive provider for numerous reasons.
Dr Fred Weaver (Los Angeles, Calif). Have you done, and
maybe it is difﬁcult in this endovascular era, but have you done
a similar kind of analysis of open repair at Dartmouth?
Dr Stone. The answer is we have not. The main reason why
we did not was because we believe that cost-effective analyses for
EVAR have already been performed. Furthermore, and at this
point, we believe irrespective of the cost proﬁle of EVAR, EVAR
is clearly here and here to stay in our respective practices. There-
fore, it is not so much a matter of whether open is more cost-palat-
able but whether we can make EVAR more cost-effective.
